Search Result

Results for "

biliary

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) Amylases (3) Antibiotic (9) Apical Sodium-Dependent Bile Acid Transporter (6) Apoptosis (1) Autophagy (3) Bacterial (7) Biochemical Assay Reagents (3) CD276/B7-H3 (1) Claudin (1) COX (1) CXCR (1) Cytochrome P450 (3) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (3) Endogenous Metabolite (24) Factor Xa (1) Fluorescent Dye (1) FXR (3) Glutathione Peroxidase (1) HDAC (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (6) Lipase (3) Microtubule/Tubulin (1) NO Synthase (1) P-glycoprotein (1) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phosphodiesterase (PDE) (3) PPAR (8) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (13) Scavenger Receptor Class B type I (SR-BI） (1) TNF Receptor (2) Transmembrane Glycoprotein (1) VEGFR (5) β-glucuronidase (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (5) Endocrinology (3) Infection (10) Inflammation/Immunology (23) Metabolic Disease (37) Neurological Disease (8)
Click Chemistry:	Azide (1)
Oligonucleotides:	Cholesterol (2)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1788

Taurocholic acid Maximum Cited Publications 31 Publications Verification N-Choloyltaurine	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-16737

Elafibranor 15+ Cited Publications GFT505	PPAR	Metabolic Disease Inflammation/Immunology
Elafibranor (GFT505) is a PPARα/δ agonist with EC₅₀s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 31 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1131

Taurocholic acid sodium salt hydrate Maximum Cited Publications 31 Publications Verification Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate	Endogenous Metabolite	Neurological Disease Metabolic Disease Inflammation/Immunology
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-109120

Odevixibat 4 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-133707

β-Muricholic acid 1 Publications Verification	Endogenous Metabolite	Metabolic Disease
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-126995

Glycohyodeoxycholic acid	Endogenous Metabolite	Metabolic Disease
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease .

HY-B0998

Dehydrocholic acid sodium Dehydrocholate sodium	Amylases Lipase Autophagy	Metabolic Disease
Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-16643

Linerixibat 10+ Cited Publications GSK2330672	Apical Sodium-Dependent Bile Acid Transporter	Infection Metabolic Disease Inflammation/Immunology
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .

HY-113315

3b-Hydroxy-5-cholenoic acid	Endogenous Metabolite	Metabolic Disease
3β-Hydroxy-5-cholenoic acid is a steroidal monohydroxy bile acid and serves as a substrate for sulfation reactions. It is applicable to the research of extrahepatic biliary atresia and recurrent intrahepatic cholestasis of pregnancy .

HY-119412

Biliatresone	Reactive Oxygen Species (ROS)	Metabolic Disease
Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model .

HY-114360

Taurohyodeoxycholic acid 2 Publications Verification	Endogenous Metabolite COX Interleukin Related Glutathione Peroxidase TNF Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula .

HY-16747

Maralixibat chloride SHP625 chloride; LUM001 chloride; Lopixibat chloride	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia .

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-160719

2-octynoic acid-BSA	Peptide-Drug Conjugates (PDCs)	Inflammation/Immunology
NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research .

HY-B1393

Dehydrocholic acid Dehydrocholate	Autophagy Amylases Lipase	Metabolic Disease
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-B1210

Pipemidic acid 1 Publications Verification	Bacterial Antibiotic	Infection
Pipemidic acid , a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid inhibits DNA gyrase. Pipemidic acid is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid can be used for the research of intestinal, urinary, and biliary tract infections .

HY-W353102

Estradiol 17-(β-D-Glucuronide)	Endogenous Metabolite P-glycoprotein	Metabolic Disease
Estradiol 17-(β-D-Glucuronide) is a D-ring glucuronide metabolite of natural estrogen formed in the liver. Estradiol 17-(β-D-Glucuronide) is a substrate of the organic anion-transporting polypeptide family (Oatp) and multidrug resistance-associated protein 2 (Mrp2). Estradiol 17-(β-D-Glucuronide) regulates MRP8-mediated transport processes and inhibits MRP8-mediated transport of dehydroepiandrosterone 3-sulfate and taurocholic acid. Estradiol 17-(β-D-Glucuronide) induces immediate, reversible reduction of bile flow and acute intrahepatic cholestasis in female rats without altering the bile acid composition in bile. Estradiol 17-(β-D-Glucuronide) can be used in studies related to intrahepatic cholestasis .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-B1043

Piromidic acid	Bacterial Antibiotic	Infection
Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .

HY-N6987

Licraside	FXR Factor Xa	Cardiovascular Disease Inflammation/Immunology
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-B2091

Azidocillin	Antibiotic Bacterial	Infection
Azidocillin, a semi-synthetic Penicillin, is an orally active β-lactam antibiotic. Azidocillin bears an azide functionality and retains on-target activity within bacteria. Azidocillin can be used to research osteitis caused by dental surgery, otitis media, enterococcal septicemia and other bacterial infectious diseases . Azidocillin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-P990059

Puxitatug INT-016; AZD8205 Antibody	ADC Antibody CD276/B7-H3	Cancer
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .

HY-118483

Benziodarone L-2329	Endogenous Metabolite	Endocrinology
Benziodarone is a potent inhibitor of S-arylglutathione transferase enzyme system. Benziodarone catalyzes BSP conjugation with GSH. Benziodarone inhibits biliary excretion of synthetic BSP-GSH conjugates .

HY-N9516

Taurodehydrocholic acid TDHC	Endogenous Metabolite	Metabolic Disease
Taurodehydrocholic acid is a biliary cholesterol secretion activator. Taurodehydrocholic acid significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid can be used in the study of cholesterol metabolism .

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Reference Standards VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-19522A

Seladelpar sodium salt 1 Publications Verification MBX-8025 sodium salt; RWJ-800025 sodium salt	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-W018512R

7-Ketolithocholic acid (Standard) 3α-Hydroxy-7-oxo-5β-cholanic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-N9516A

Taurodehydrocholic acid sodium	Endogenous Metabolite	Metabolic Disease
Taurodehydrocholic acid sodium is a biliary cholesterol secretion activator. Taurodehydrocholic acid sodium significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid sodium can be used in the study of cholesterol metabolism .

HY-176510

Elafibranor sulfoxide	PPAR Drug Metabolite	Metabolic Disease Inflammation/Immunology
Elafibranor (GFT505) sulfoxide is a sulfoxide metabolite of Elafibranor (HY-16737). Elafibranor is a PPARα/δ agonist with EC₅₀s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .

HY-B2119

Sodium tauroglycocholate Tauroglycocholic acid sodium salt	Biochemical Assay Reagents	Metabolic Disease
Sodium tauroglycocholate (Tauroglycocholic acid sodium salt) is a multifunctional surfactant and penetration enhancer that can serve as a cholegraphic contrast agent. In organic solvents, Sodium tauroglycocholate embeds and stabilizes invertase by forming reverse micelles, and prolongs its active lifespan. In terms of transdermal absorption, Sodium tauroglycocholate effectively regulates the flux of aminophylline through snake slough by binding to keratin filaments, disrupting keratinocytes and altering lipid components of the stratum corneum. It exhibits rapid penetration characteristics without lag time at a concentration of 100 μg/mL. Sodium tauroglycocholate does not interfere with the hepatic uptake of Gd-EOB-DTPA by the bile acid transport system in rat hepatocytes .

HY-W653842

Taurocholic acid-d8 sodium Sodium taurocholate-d8 (Standard); N-Choloyltaurine-d8 sodium	Isotope-Labeled Compounds VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid-d₈ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-19522C

Seladelpar Lysine dihydrate 1 Publications Verification MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate	PPAR	Metabolic Disease
Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC₅₀ of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .

HY-W013766

Pipemidic acid trihydrate 1 Publications Verification	Bacterial Antibiotic	Infection
Pipemidic acid trihydrate, a derivative of Piromidic acid, is an antibacterial agent. Pipemidic acid trihydrate inhibits DNA gyrase. Pipemidic acid trihydrate is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Pipemidic acid trihydrate can be used for the research of intestinal, urinary, and biliary tract infections .

HY-B1788R

Taurocholic acid (Standard) N-Choloyltaurine (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-113086

CE(16:1(9Z)) 16:1(9Z) CE; 16:1(9Z) Cholesterol ester; Cholesterol Palmitoleate	Endogenous Metabolite	Cardiovascular Disease
CE(16:1(9Z)) (16:1(9Z) CE) is a cholesterol ester. Plasma levels of cholesteryl palmitoleate are increased in ApoE ^-/- mice exposed to cigarette smoke and in pediatric patients with biliary atresia. Cholesteryl palmitoleate has been used as a standard for the identification of cholesterol esters in human meibomian gland secretions.

HY-105047

Fluorescein lisicol NRL972	Biochemical Assay Reagents	Metabolic Disease
Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research .

HY-201296A

Tauroursocholic acid sodium TUCA sodium	Drug Isomer	Cancer
Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid (HY-B1788). Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research .

HY-154857

1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine	Scavenger Receptor Class B type I (SR-BI）	Cancer
1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine is a glycerophosphorylcholine, consisting of glycerol phosphate, choline and palmitic acid. It accumulates in vivo at sites of oxidative stress. 1-Palmitoyl-2-succinyl-sn-glycerophosphorylcholine may be a ligand of scavenger receptors class B, while oxidized phospholipids oxPC(CD36) are potent ligands of scavenger receptors class B (CD36 and SR-BI). Oxidized phospholipids (oxPLs) also play an important role in tumor apoptosis, may be elevated in malignant biliary strictures .

HY-106162A

ONO-1714	NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ONO-1714 is an orally active nitric oxide synthase inhibitor. ONO-1714 attenuates endotoxin-induced acute lung injury, reduces intestinal ischemia–reperfusion injury, represses biliary carcinogenesis .

HY-16737R

Elafibranor (Standard) GFT505 (Standard)	PPAR Reference Standards	Metabolic Disease Inflammation/Immunology
Elafibranor (Standard) is the analytical standard of Elafibranor. This product is intended for research and analytical applications. Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis .

HY-19522B

Seladelpar (lysine) 1 Publications Verification MBX-8025 (lysine)	PPAR	Metabolic Disease
Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC₅₀ of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .

HY-19522R

Seladelpar (Standard) MBX-8025 (Standard); RWJ-800025 (Standard)	PPAR Reference Standards	Metabolic Disease
Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-E70413

Amino acid arylamidase, hog kidney	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Amino acid arylamidase, hog kidney is a metalloprotease that can hydrolyze proteins or peptides containing free α-amino or α-imino groups, playing a crucial role in amino acid metabolism and protein digestion. Its hydrolytic activity can be blocked by acetylation of the N-terminus. Amino acid arylamidase, hog kidney can be used in research on hepatic diseases, biliary diseases, and heart failure .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120R

Odevixibat (Standard) A4250 (Standard)	Apical Sodium-Dependent Bile Acid Transporter Reference Standards	Metabolic Disease
Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

Cat. No.	Product Name	Type

HY-105047

Fluorescein lisicol NRL972	Fluorescent Dye
Fluorescein lisicol is a fluorescent-labelled bile salt and a marker of hepatic biliary transporter function. Fluorescein lisicol can be used for metabolic research .

HY-113238F

FITC-Lithocholic acid 3-sulfate FITC-Sulfolithocholic acid	Fluorescent Dye
FITC-Lithocholic acid 3-sulfate (FITC-Sulfolithocholic acid) is a FITC-labeled Lithocholic acid 3-sulfate, which is a sulfated biliary metabolite. Lithocholic acid 3-sulfate selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate can be used for the research of pathogenesis of cholestatic liver diseases .

Cat. No.	Product Name	Target	Research Area

HY-118534

Cyclobutyrol BRN-2209058	Endogenous Metabolite	Endocrinology
Cyclobutyrol is a potent choleretic agent. Cyclobutyrol also inhibits biliary lipid secretion. Cyclobutyrol induces choleretic is unrelated to bile acids. Cyclobutyrol and bile acids do not compete for the hepatobiliar transport mechanisms[1]

HY-P1654A

A20FMDV2-Cys	Integrin	Cancer
A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991564

Arcotatug IBI-343 antibody; HB37A6; TAK-921 Antibody	ADC Antibody Claudin	Cancer
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs .

HY-P99404

Quetmolimab E6011	CXCR	Inflammation/Immunology Cancer
Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis .

HY-P990059

Puxitatug INT-016; AZD8205 Antibody	ADC Antibody CD276/B7-H3	Cancer
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .

HY-P991554

FFP-104	TNF Receptor	Inflammation/Immunology
FFP-104 is a humanized IgG4 monoclonal antibody inhibitor targeting TNFRSF5/CD40. VX70 can be used for chronic autoimmune liver diseases research, such as primary biliary cholangitis (PBC) .

HY-P992021

WM-A1-3389	Transmembrane Glycoprotein	Cancer
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN−γ, and TNF−α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1788

Taurocholic acid Maximum Cited Publications 31 Publications Verification N-Choloyltaurine	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 31 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	Structural Classification Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	VEGFR Endogenous Metabolite
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1131

Taurocholic acid sodium salt hydrate Maximum Cited Publications 31 Publications Verification Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate	Structural Classification Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .

HY-133707

β-Muricholic acid 1 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
β-Muricholic acid is a potent and orally active biliary cholesterol-desaturating agent. β-Muricholic acid prevents cholesterol gallstones. β-Muricholic acid inhibits lipid accumulation. β-Muricholic acid has the potential for the research of nonalcoholic fatty liver disease (NAFLD) .

HY-126995

Glycohyodeoxycholic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycohyodeoxycholic acid is a glycine-conjugated bile acid and also a metabolite of Hyodeoxycholic acid (HY-N0169). The serum level of Glycohyodeoxycholic acid is negatively correlated with the severity of non-alcoholic fatty liver disease. Glycohyodeoxycholic acid can be used in research related to non-alcoholic fatty liver disease .

HY-B0998

Dehydrocholic acid sodium Dehydrocholate sodium	Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Steroids Source Classification	Amylases Lipase Autophagy
Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-113315

3b-Hydroxy-5-cholenoic acid	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
3β-Hydroxy-5-cholenoic acid is a steroidal monohydroxy bile acid and serves as a substrate for sulfation reactions. It is applicable to the research of extrahepatic biliary atresia and recurrent intrahepatic cholestasis of pregnancy .

HY-119412

Biliatresone	Flavonoids other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Isoflavones Source Classification	Reactive Oxygen Species (ROS)
Biliatresone is a natural toxin isolated from Dysphania glomulifera and D. littoralis. Biliatresone, a 1,2-diaryl-2-propenone class of isoflavonoid, produces extrahepatic biliary atresia in a zebrafish model .

HY-114360

Taurohyodeoxycholic acid 2 Publications Verification	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite COX Interleukin Related Glutathione Peroxidase TNF Receptor
Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula .

HY-W353102

Estradiol 17-(β-D-Glucuronide)	Structural Classification Monophenols Classification of Application Fields Phenols Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite P-glycoprotein
Estradiol 17-(β-D-Glucuronide) is a D-ring glucuronide metabolite of natural estrogen formed in the liver. Estradiol 17-(β-D-Glucuronide) is a substrate of the organic anion-transporting polypeptide family (Oatp) and multidrug resistance-associated protein 2 (Mrp2). Estradiol 17-(β-D-Glucuronide) regulates MRP8-mediated transport processes and inhibits MRP8-mediated transport of dehydroepiandrosterone 3-sulfate and taurocholic acid. Estradiol 17-(β-D-Glucuronide) induces immediate, reversible reduction of bile flow and acute intrahepatic cholestasis in female rats without altering the bile acid composition in bile. Estradiol 17-(β-D-Glucuronide) can be used in studies related to intrahepatic cholestasis .

HY-W018512

7-Ketolithocholic acid 4 Publications Verification 3α-Hydroxy-7-oxo-5β-cholanic acid	Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite
7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-B1043

Piromidic acid	Infection Classification of Application Fields Antibiotics Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Bacterial Antibiotic
Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .

HY-N6987

Licraside	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	FXR Factor Xa
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-N9516

Taurodehydrocholic acid TDHC	Animals Steroids Source Classification	Endogenous Metabolite
Taurodehydrocholic acid is a biliary cholesterol secretion activator. Taurodehydrocholic acid significantly increases the expression of Abcg5 and decreases the expression of abc8. Taurodehydrocholic acid can be used in the study of cholesterol metabolism .

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Structural Classification Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Reference Standards VEGFR Endogenous Metabolite
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-W018512R

7-Ketolithocholic acid (Standard) 3α-Hydroxy-7-oxo-5β-cholanic acid (Standard)	Structural Classification Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
7-Ketolithocholic acid (Standard) is the analytical standard of 7-Ketolithocholic acid. This product is intended for research and analytical applications. 7-Ketolithocholic acid (3α-Hydroxy-7-oxo-5β-cholanic acid), a bile acid, can be absorbed and suppresses endogenous bile acid production and biliary cholesterol secretion .

HY-B1788R

Taurocholic acid (Standard) N-Choloyltaurine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-B1043R

Piromidic acid (Standard)	Structural Classification Antibiotics Antibacterial Disease Research Endogenous metabolite Other Antibiotics Source Classification	Reference Standards Bacterial Antibiotic
Piromidic acid (Standard) is the analytical standard of Piromidic acid. This product is intended for research and analytical applications. Piromidic acid is an antibacterial agent. Piromidic acid is active against gramnegative bacteria and staphylococci and can be used for the research of intestinal, urinary, and biliary tract infections .

Species:	Human (3)
Tag:	SUMO (1) His (2) Tag Free (1)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P72129

	CEACAM1 Protein, Human Antigen CD66; BGP 1; BGP; BGP-1; BGPI; biliary glycoprotein 1; biliary glycoprotein adhesion molecule; biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with tag free.

HY-P72129A

	CEACAM1 Protein, Human (N-His) Antigen CD66; BGP 1; BGP; BGP-1; BGPI; biliary glycoprotein 1; biliary glycoprotein adhesion molecule; biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human (N-His) is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P72128

	CEACAM1 Protein, Human (His-SUMO) Antigen CD66; BGP 1; BGP; BGP-1; BGPI; biliary glycoprotein 1; biliary glycoprotein adhesion molecule; biliary glycoprotein; Carcinoembryonic antigen related cell adhesion molecule 1; carcinoembryonic antigen-related cell adhesion molecule 1 biliary glycoprotein; ; Carcinoembryonic antigen-related cell adhesion molecule 1; CD66a; CD66a antigen; CEACAM1; CEAM1_HUMAN; meconium antigen 100	Human	E. coli
	CEACAM1 protein is involved in various biological processes. It is phosphorylated by the insulin receptor (INSR) in response to insulin stimulation, thereby promoting insulin clearance and regulating hepatic lipogenesis. CEACAM1 Protein, Human (His-SUMO) is the recombinant human-derived CEACAM1 protein, expressed by E. coli , with N-10*His, N-SUMO labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W653842

Taurocholic acid-d8 sodium
Taurocholic acid-d₈ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-109120S

Odevixibat-d5
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-W653893

Taurocholic acid-d5 sodium
Taurocholic acid-d₅ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788S2

Taurocholic acid-d5
Taurocholic acid-d₅ (Taurocholic Acid-d₅) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545S2

Taurocholic acid-d4-1 sodium
Taurocholic acid-d₄-1 sodium (Sodium taurocholate-d₄-1) is the deuterium labeled Taurocholic acid sodium (HY-N0545). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

Host:	Mouse (2)
Reactivity:	Human (2) Mouse (1) Rabbit (1)
Application:	ICC/IF (1) IP (1) WB (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P85448

	Pyruvate Dehydrogenase E2 Antibody (YA5140) DLAT; DLTA; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; mitochondrial; 70 kDa mitochondrial autoantigen of primary biliary cirrhosis; PBC; Dihydrolipoamide acetyltransferase component of pyruva	WB	Human, Rabbit
	Pyruvate Dehydrogenase E2 Antibody (YA5140) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Pyruvate Dehydrogenase E2.

HY-P85556

	Pyruvate Dehydrogenase E2 Antibody (YA5248) 70 kDa mitochondrial autoantigen of primary biliary cirrhosis; anti DLAT; Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex; Dihydrolipoamide; Dihydrolipoamide S Acetyltransferase; Dihydrolipoamide S-acetyltransferase; E2 component of pyruvate dehydrogenase complex; Dihydrolipoamide S-Acetyltransferase; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex mitochondrial; DLAT; DLAT; DLTA; E2; E2 component of pyruvate dehydrogenase complex; M2 antigen complex 70 kDa subunit; M2 Antigen Complex 70kD Subunit; mitochondrial; ODP2_HUMAN; PBC; PDC E2; PDC-E2; PDCE2; Pyruvate dehydrogenase complex component E2; Pyruvate dehydrogenase complex E2 subunit; S acetyltransferase component of pyruvate dehydrogenase complex.	WB, ICC/IF, IP	Human, Mouse
	Pyruvate Dehydrogenase E2 Antibody (YA5248) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Pyruvate Dehydrogenase E2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-B2091

Azidocillin		Azide
Azidocillin, a semi-synthetic Penicillin, is an orally active β-lactam antibiotic. Azidocillin bears an azide functionality and retains on-target activity within bacteria. Azidocillin can be used to research osteitis caused by dental surgery, otitis media, enterococcal septicemia and other bacterial infectious diseases . Azidocillin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name		Classification

HY-B1393

Dehydrocholic acid Dehydrocholate		Cholesterol
Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .

HY-113086

CE(16:1(9Z)) 16:1(9Z) CE; 16:1(9Z) Cholesterol ester; Cholesterol Palmitoleate		Cholesterol
CE(16:1(9Z)) (16:1(9Z) CE) is a cholesterol ester. Plasma levels of cholesteryl palmitoleate are increased in ApoE ^-/- mice exposed to cigarette smoke and in pediatric patients with biliary atresia. Cholesteryl palmitoleate has been used as a standard for the identification of cholesterol esters in human meibomian gland secretions.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

biliary

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products